Saskia C. van der Boor

A double-blind, placebo-controlled phase 1/2a trial of the genetically attenuated malaria vaccine PfSPZ-GA1

S. Hoffman, C. Janse, G. van Gemert, 2020, Science Translational Medicine.

Mid-Liver Stage Arrest of Plasmodium falciparum Schizonts in Primary Porcine Hepatocytes

T. Bousema, G. van Gemert, R. Sauerwein, 2022, Frontiers in Cellular and Infection Microbiology.

Safety, tolerability, and Plasmodium falciparum transmission-reducing activity of monoclonal antibody TB31F: a single-centre, open-label, first-in-human, dose-escalation, phase 1 trial in healthy malaria-naive adults

T. Bousema, J. Aponte, G. van Gemert, 2022, The Lancet. Infectious diseases.

Spontaneously reported adverse events following COVID-19 basic and booster immunizations in the Netherlands

F. van Hunsel, Joep H G Scholl, L. Rolfes, 2023, Vaccine.

Modeling the Impact of a Highly Potent Plasmodium falciparum Transmission-Blocking Monoclonal Antibody in Areas of Seasonal Malaria Transmission

T. Bousema, J. Aponte, G. Charles, 2023, Journal of Infectious Diseases.

Whole sporozoite immunization with Plasmodium falciparum strain NF135 in a randomized trial

G. van Gemert, R. Sauerwein, C. Ockenhouse, 2023, BMC Medicine.